Perrigo: Double-Digit Dividend At A Bargain Price

12% dividend yield and a P/E of 4.3 signal deep valuation upside for Perrigo (PRGO). Management's Three-S Plan targets $80M–$100M in annual cost savings by 2027 as the company refocuses on its core OTC store-brand business after divestitures and prior acquisition missteps. Trading at a significant discount to fair value, these measures should support margin improvement and sustainable dividend growth, making PRGO a compelling value opportunity.

Analysis

Retailers are the hidden beneficiaries of a stronger private-label operator: incremental margin accrues to them via lower COGS and reduced promotional leakage, which in turn raises their willingness to expand shelf space and exclusive SKUs. That dynamic pressures national consumer-health brands' top lines and forces them to either concede share, increase trade spend, or accelerate SKU rationalization — expect elevated promotional activity in Q2–Q4 as incumbents defend placement.

Operational execution is the linchpin: working-capital swings, one-time restructuring costs, or a single product recall can erase near-term cash available for distributions and rerating. Key catalysts to monitor are sequential improvement in free-cash-flow conversion (not just adjusted EBITDA), margin expansion cadence over the next two quarters, and any changes in retailer contract terms that transfer pricing pressure back to the supplier.

The market is polarized: one side prizes income and low headline valuation, the other discounts execution risk and retailer concentration. If management consistently converts announced initiatives into cash within the next 4–8 quarters, equity upside from multiple expansion and buyback optionality could be material; conversely, a missed milestone or retailer destocking episode would likely compress the multiple sharply and reset investor expectations.

Key Decisions for Investors

• Long PRGO (size 2–4% portfolio) with built-in downside protection: buy shares and pair with 9–12 month OTM puts (~15–20% below entry) to cap tail risk. Timeframe 6–12 months; base case upside 30–50% if cost execution and cash conversion meet guidance; primary risk is a dividend cut or retail destocking that can trigger >30% drawdown.
• Relative-value pair: long PRGO / short PG (equal notional) for 6–12 months to isolate private‑label share gain vs national-brand defensives. Expect asymmetric payoff if private‑label shelf gains accelerate; risk is a sector-wide flight to safety that lifts both legs.
• Covered-call income sleeve: buy-and-hold PRGO and sell 3-month slightly ITM calls to harvest yield while waiting for re‑rating. Use rolling strikes and maintain a 10–15% cash buffer to buy back if adverse gap risk appears around earnings; this boosts carry but caps upside near-term.
• Event-trigger trade (opportunistic): Add or scale on a clear cash‑flow improvement signal—two consecutive quarters of FCF conversion improvement or upgraded guidance. Use alerts to add on confirmation; set stop-loss at a single-quarter miss to limit execution risk.